Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

FLT3: ITDoes matter in leukemia.

M Levis1, D Small

  • 1Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.

Leukemia
|September 13, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low-Dose Radiotherapy for Primary Cutaneous Indolent B-Cell Lymphomas: a Multicenter Retrospective Study.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2025
Same author

Understanding clinical practice and survival outcomes in patients with unresectable stage III non-small-cell lung cancer in a single centre in Quebec.

Current oncology (Toronto, Ont.)·2020
Same author

Erratum to "The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma" [Lung Cancer 132 (June) (2019) 36-38].

Lung cancer (Amsterdam, Netherlands)·2019
Same author

The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma.

Lung cancer (Amsterdam, Netherlands)·2019
Same author

Does the presence of emphysema increase the risk of radiation pneumonitis in lung cancer patients?

Current oncology (Toronto, Ont.)·2019
Same author

Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same journal

Linperlisib enhances MUC1-Tn CAR T cell efficacy by inhibiting EGR1/DUSP2 axis to prevent CAR T cell exhaustion.

Leukemia·2026
Same journal

CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.

Leukemia·2026
Same journal

Single-cell architecture of purinergic signaling in human cord blood hematopoietic stem and progenitor cells.

Leukemia·2026
Same journal

Feasibility and safety of rapid glofitamab ramp-up.

Leukemia·2026
Same journal

Single-cell DNA methylation analysis uncovers epigenetic pathways in the transformation of MDS to AML.

Leukemia·2026
Same journal

PD-L2 is associated with lineage-related transcriptional programs distinct from PD-L1 in primary mediastinal large B-cell lymphoma.

Leukemia·2026
See all related articles

FMS-like tyrosine kinase-3 (FLT3) mutations are common in acute myeloid leukemia, leading to poor prognosis. Small-molecule FLT3 inhibitors are being developed as a promising therapeutic strategy for these patients.

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • FMS-like tyrosine kinase-3 (FLT3) is crucial for hematopoietic and immune system development.
  • Activating FLT3 mutations are the most frequent molecular abnormality in acute myeloid leukemia (AML).
  • FLT3 mutations are implicated in other hematologic malignancies and are associated with poor patient prognosis.

Purpose of the Study:

  • To review the molecular biology of FLT3 mutations.
  • To discuss the clinical impact of FLT3 mutations in hematologic malignancies.
  • To summarize the therapeutic potential of novel FLT3 inhibitors.

Main Methods:

  • Literature review of FLT3.
  • Analysis of molecular biology data.
  • Evaluation of clinical impact and therapeutic strategies.

Related Experiment Videos

Main Results:

  • FLT3 mutations are prevalent in AML, driving disease progression.
  • FLT3 mutations confer a poor prognosis in AML patients.
  • Several small-molecule FLT3 inhibitors show therapeutic promise.

Conclusions:

  • Targeting FLT3 is a critical therapeutic strategy for AML with FLT3 mutations.
  • Ongoing development of FLT3 inhibitors offers new hope for patients.
  • Further research is needed to optimize FLT3-targeted therapies.